Patents by Inventor David Kirmayer

David Kirmayer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210315803
    Abstract: Provided herein are compositions of injectable antibiotics for veterinary use. The compositions are characterized by forming a gel at animal physiological temperature, said gel being characterized by a stable and repeatable release profile of the antibiotic. The compositions comprise high loading of drug in poloxamer solutions with addition of a co-solvent, and preferably with an addition of a cellulose derivative at least partially soluble in organic solvents. Methods of treatment of veterinary infections are also provided.
    Type: Application
    Filed: September 5, 2019
    Publication date: October 14, 2021
    Applicant: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD.
    Inventors: Michael FRIEDMAN, David KIRMAYER, Zakhar NUDELMAN, Amnon HOFFMAN, Eran LAVY, Ayala BAR-HAI, Irith GATI
  • Publication number: 20190298649
    Abstract: Provided herein injectable implant compositions useful for acceleration of bone fracture healing, treatment of dental or oral pathologies, and controlled drug delivery.
    Type: Application
    Filed: September 19, 2017
    Publication date: October 3, 2019
    Inventors: Michael FRIEDMAN, David KIRMAYER, Rami MOSHEIFF, Jacob RACHMILEWITZ, Amal KHOURY, Doron STEINBERG
  • Patent number: 9801826
    Abstract: The invention provides for the use of an accordion pill comprising levodopa for the treatment of symptoms of Parkinson's disease in a subject in need thereof over a 24 hour period, to be administered to the subject in a twice daily administration regimen, with an interval of about 8 to about 10 hours between the first dose and the second dose, and with an interval of about 14 to about 16 hours between the second dose and the first dose of the following day. The twice daily administration regimen provides a stable blood plasma level of levodopa in the subject after multiple administrations and is effective in treating the symptoms of Parkinson's disease over a 24 hour period.
    Type: Grant
    Filed: January 11, 2017
    Date of Patent: October 31, 2017
    Assignee: INTEC PHARMA LTD.
    Inventors: Nadav Navon, David Kirmayer, Julia Shvetz, Elena Kluev, Eva Abramov, Zeev Weiss, Giora Carni
  • Patent number: 9693981
    Abstract: A biodegradable, multi-layered controlled release gastroretentive dosage form which is optionally divided into a first dosage of zaleplon for controlled release and a second dosage of zaleplon for immediate release in the stomach and gastrointestinal tract of a patient, folded into a capsule which disintegrates upon contact with gastric juice and the gastroretentive dosage form unfolds rapidly upon contact with gastric juice. The biodegradable, multi-layered gastroretentive dosage forms of the invention provide efficient sleep induction with good sleep maintenance and minimal next day residual effects.
    Type: Grant
    Filed: October 19, 2009
    Date of Patent: July 4, 2017
    Assignee: INTEC PHARMA LTD.
    Inventors: Suher Masri, Eytan Moor, David Kirmayer, Elena Kluev, Giora Carni, Nadav Navon
  • Patent number: 9655859
    Abstract: The invention provides for the use of an accordion pill comprising levodopa for the treatment of symptoms of Parkinson's disease in a subject in need thereof over a 24 hour period, to be administered to the subject in a twice daily administration regimen, with an interval of about 8 to about I 0 hours between the first dose and the second dose, and with an interval of about 14 to about 16 hours between the second dose and the first dose of the following day. The twice daily administration regimen provides a stable blood plasma level of levodopa in the subject after multiple administrations and is effective in treating the symptoms of Parkinson's disease over a 24 hour period.
    Type: Grant
    Filed: February 3, 2016
    Date of Patent: May 23, 2017
    Assignee: INTEC PHARMA LTD.
    Inventors: Nadav Navon, David Kirmayer, Julia Shvetz, Elena Kluev, Eva Abramov, Zeev Weiss, Giora Carni
  • Publication number: 20170119679
    Abstract: The invention provides for the use of an accordion pill comprising levodopa for the treatment of symptoms of Parkinson's disease in a subject in need thereof over a 24 hour period, to be administered to the subject in a twice daily administration regimen, with an interval of about 8 to about 10 hours between the first dose and the second dose, and with an interval of about 14 to about 16 hours between the second dose and the first dose of the following day. The twice daily administration regimen provides a stable blood plasma level of levodopa in the subject after multiple administrations and is effective in treating the symptoms of Parkinson's disease over a 24 hour period.
    Type: Application
    Filed: January 11, 2017
    Publication date: May 4, 2017
    Inventors: Nadav Navon, David Kirmayer, Julia Shvetz, Elena Kluev, Eva Abramov, Zeev Weiss, Giora Carni
  • Publication number: 20170119664
    Abstract: A gastroretentive drug formulation for the sustained release of an active agent in the gastrointestinal tract comprises internal layer or compartment comprising an active agent and one or more pharmaceutical excipients, of which at least one is a polymer and two membranes forming together an envelope around the inner membrane, each membrane comprising at least one polymeric combination of an enteric polymer which is not soluble in gastric juice, and an hydrophilic swelling polymer, and at least one plasticizer.
    Type: Application
    Filed: January 11, 2017
    Publication date: May 4, 2017
    Inventors: Nadav Navon, Eytan Moor, David Kirmayer, Elena Kluev, Giora Carni
  • Publication number: 20170087091
    Abstract: The invention provides for the use of an accordion pill comprising levodopa for the treatment of symptoms of Parkinson's disease in a subject in need thereof over a 24 hour period, to be administered to the subject in a twice daily administration regimen, with an interval of about 8 to about I 0 hours between the first dose and the second dose, and with an interval of about 14 to about 16 hours between the second dose and the first dose of the following day. The twice daily administration regimen provides a stable blood plasma level of levodopa in the subject after multiple administrations and is effective in treating the symptoms of Parkinson's disease over a 24 hour period.
    Type: Application
    Filed: February 3, 2016
    Publication date: March 30, 2017
    Inventors: Nadav Navon, David Kirmayer, Julia Shvetz, Elena Kluev, Eva Abramov, Zeev Weiss, Giora Carni
  • Patent number: 9554991
    Abstract: A gastroretentive drug formulation for the sustained release of an active agent in the gastrointestinal tract comprises an internal layer or compartment comprising an active agent and one or more pharmaceutical excipients, of which at least one is a polymer and two membranes forming together an envelope around the inner membrane, each membrane comprising at least one polymeric combination of an enteric polymer which is not soluble in gastric juice, and an hydrophilic swelling polymer, and at least one plasticizer.
    Type: Grant
    Filed: January 14, 2016
    Date of Patent: January 31, 2017
    Assignee: INTEC PHARMA LTD.
    Inventors: Nadav Navon, Eytan Moor, David Kirmayer, Elena Kluev, Giora Carni
  • Publication number: 20160220495
    Abstract: The invention provides for the use of an accordion pill comprising levodopa for the treatment of symptoms of Parkinson's disease in a subject in need thereof over a 24 hour period, to be administered to the subject in a twice daily administration regimen, with an interval of about 8 to about I 0 hours between the first dose and the second dose, and with an interval of about 14 to about 16 hours between the second dose and the first dose of the following day. The twice daily administration regimen provides a stable blood plasma level of levodopa in the subject after multiple administrations and is effective in treating the symptoms of Parkinson's disease over a 24 hour period.
    Type: Application
    Filed: February 3, 2016
    Publication date: August 4, 2016
    Inventors: Nadav Navon, David Kirmayer, Julia Shvetz, Elena Kluev, Eva Abramov, Zeev Weiss, Giora Carni
  • Publication number: 20160199300
    Abstract: A gastroretentive drug formulation for the sustained release of an active agent in the gastrointestinal tract comprises an internal layer or compartment comprising an active agent and one or more pharmaceutical excipients, of which at least one is a polymer and two membranes forming together an envelope around the inner membrane, each membrane comprising at least one polymeric combination of an enteric polymer which is not soluble in gastric juice, and an hydrophilic swelling polymer, and at least one plasticizer.
    Type: Application
    Filed: January 14, 2016
    Publication date: July 14, 2016
    Inventors: Nadav Navon, Eytan Moor, David Kirmayer, Elena Kluev, Giora Carni
  • Patent number: 9259387
    Abstract: A gastroretentive drug formulation for the sustained release of an active agent in the gastrointestinal tract comprises an internal layer or compartment comprising an active agent and one or more pharmaceutical excipients, of which at least one is a polymer and two membranes forming together an envelope around the inner membrane, each membrane comprising at least one polymeric combination of an enteric polymer which is not soluble in gastric juice, and an hydrophilic swelling polymer, and at least one plasticizer.
    Type: Grant
    Filed: May 18, 2015
    Date of Patent: February 16, 2016
    Assignee: INTEC PHARMA LTD.
    Inventors: Nadav Navon, Eytan Moor, David Kirmayer, Elena Kluev, Giora Carni
  • Publication number: 20150366832
    Abstract: A gastroretentive drug formulation for the sustained release of an active agent in the gastrointestinal tract comprises an internal layer or compartment comprising an active agent and one or more pharmaceutical excipients, of which at least one is a polymer and two membranes forming together an envelope around the inner membrane, each membrane comprising at least one polymeric combination of an enteric polymer which is not soluble in gastric juice, and an hydrophilic swelling polymer, and at least one plasticizer.
    Type: Application
    Filed: May 18, 2015
    Publication date: December 24, 2015
    Inventors: Nadav Navon, Eytan Moor, David Kirmayer, Elena Kluev, Giora Carni
  • Patent number: 9072663
    Abstract: A gastroretentive drug formulation for the sustained release of an active agent in the gastrointestinal tract comprises an internal layer or compartment comprising an active agent and one or more pharmaceutical excipients, of which at least one is a polymer and two membranes forming together an envelope around the inner membrane, each membrane comprising at least one polymeric combination of an enteric polymer which is not soluble in gastric juice, and an hydrophilic swelling polymer, and at least one plasticizer.
    Type: Grant
    Filed: July 2, 2014
    Date of Patent: July 7, 2015
    Assignee: INTEC PHARMA LTD.
    Inventors: Nadav Navon, Eytan Moor, David Kirmayer, Elena Kluev, Giora Carni
  • Publication number: 20150010624
    Abstract: A gastroretentive drug formulation for the sustained release of an active agent in the gastrointestinal tract comprises an internal layer or compartment comprising an active agent and one or more pharmaceutical excipients, of which at least one is a polymer and two membranes forming together an envelope around the inner membrane, each membrane comprising at least one polymeric combination of an enteric polymer which is not soluble in gastric juice, and an hydrophilic swelling polymer, and at least one plasticizer.
    Type: Application
    Filed: July 2, 2014
    Publication date: January 8, 2015
    Inventors: Nadav Navon, Eytan Moor, David Kirmayer, Elena Kluev, Giora Carni
  • Publication number: 20140314842
    Abstract: A gastroretentive drug formulation for the sustained release of an active agent in the gastrointestinal tract comprises an internal layer or compartment comprising an active agent and one or more pharmaceutical excipients, of which at least one is a polymer and two membranes forming together an envelope around the inner membrane, each membrane comprising at least one polymeric combination of an enteric polymer which is not soluble in gastric juice, and an hydrophilic swelling polymer, and at least one plasticizer.
    Type: Application
    Filed: July 2, 2014
    Publication date: October 23, 2014
    Inventors: Nadav Navon, Eytan Moor, David Kirmayer, Elena Kluev, Giora Carni
  • Patent number: 8771730
    Abstract: A gastroretentive drug formulation for the sustained release of an active agent in the gastrointestinal tract comprises an internal layer or compartment comprising an active agent and one or more pharmaceutical excipients, of which at least one is a polymer and two membranes forming together an envelope around the inner membrane, each membrane comprising at least one polymeric combination of an enteric polymer which is not soluble in gastric juice, and an hydrophilic swelling polymer, and at least one plasticizer.
    Type: Grant
    Filed: April 17, 2009
    Date of Patent: July 8, 2014
    Assignee: Intec Pharma Ltd.
    Inventors: Nadav Navon, Eytan Moor, David Kirmayer, Elena Kluev, Giora Carni
  • Publication number: 20140017303
    Abstract: The invention provides for the use of an accordion pill comprising levodopa for the treatment of symptoms of Parkinson's disease in a subject in need thereof over a 24 hour period, to be administered to the subject in a twice daily administration regimen, with an interval of about 8 to about 10 hours between the first dose and the second dose, and with an interval of about 14 to about 16 hours between the second dose and the first dose of the following day. The twice daily administration regimen provides a stable blood plasma level of levodopa in the subject after multiple administrations and is effective in treating the symptoms of Parkinson's disease over a 24 hour period.
    Type: Application
    Filed: November 1, 2011
    Publication date: January 16, 2014
    Applicant: INTEC PHARMA LTD.
    Inventors: Nadav Navon, David Kirmayer, Julia Shvetz, Elena Kluev, Eva Abramov, Zeev Weiss, Giora Carni
  • Publication number: 20120321706
    Abstract: Disclosed is a multi-layered gastroretentive dosage form for the controlled release of a poorly soluble drug or diagnostic in the stomach and gastrointestinal tract of a patient, folded into a capsule which disintegrates rapidly and the said multi-layered dosage form unfolds rapidly upon contact with the gastric juice. The mechanisms of the gastric retention are not dependent on and do not influence the materials and methods used in controlling the release of the said poorly soluble drug.
    Type: Application
    Filed: October 19, 2010
    Publication date: December 20, 2012
    Applicant: INTEC PHARMA LTD.
    Inventors: Suher Masri, Eytan Moor, David Kirmayer, Elena Kluev, Giora Carni, Nadav Navon
  • Publication number: 20120021051
    Abstract: A biodegradable, multi-layered controlled release gastroretentive dosage form which is optionally divided into a first dosage of zaleplon for controlled release and a second dosage of zaleplon for immediate release in the stomach and gastrointestinal tract of a patient, folded into a capsule which disintegrates upon contact with gastric juice and the gastroretentive dosage form unfolds rapidly upon contact with gastric juice. The biodegradable, multi-layered gastroretentive dosage forms of the invention provide efficient sleep induction with good sleep maintenance and minimal next day residual effects.
    Type: Application
    Filed: October 19, 2009
    Publication date: January 26, 2012
    Applicant: Intec Pharma Ltd.
    Inventors: Suher Masri, Eytan Moor, David Kirmayer, Elena Kluev, Giora Carni, Nadav Navon